This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.




  Mobile version    RSS    Subscribe    Unsubscribe    Archive    Media Kit Dec. 31, 2012

Home   The Society   Meetings   Advocacy   Contact Us

 


As 2012 comes to a close, ASTS would like to wish its members, corporate partners, and all transplant professionals a safe and happy holiday season. As we reflect on the past year in the field of transplantation, we would like to provide readers of the ASTS Newsbrief with a look at the most accessed articles from 2012. Our regular publication will resume Monday, Jan. 14, 2013.

Donation after cardiac death liver transplantation: Time for policy to catch up with practice
Liver Transplantation    Share    Share on FacebookTwitterShare on LinkedinE-mail article
From Jan. 17, 2012: Donation after brain death is the predominant source of organs for transplantation, even though brain death accounts for only a small percentage of all-cause mortality in the United States. In contrast, cardiovascular death is a leading cause of mortality. Therefore, donation after cardiac death represents an attractive strategy for remedying organ shortage and improving transplant wait-list mortality. More



The reward for donating a kidney: No insurance
The New York Times    Share    Share on FacebookTwitterShare on LinkedinE-mail article
From June 18, 2012: When Erika Royer's lupus led to kidney failure four years ago, her father, Radburn, was able to give her an extraordinary gift: a kidney. Royer, now 31, regained her kidney function, no longer needs dialysis and has been able to return to work. But because of his donation, her father, a physically active 53-year-old, has been unable to obtain private health insurance. More

Study: Stem cells let kidney transplant patients skip rejection drugs
Bloomberg    Share    Share on FacebookTwitterShare on LinkedinE-mail article
From March 12, 2012: Kidney transplant patients given a mixture of stem cells from their organ donor were able to quit taking anti-rejection medicine in a small study, suggesting that life-long reliance on the toxic drugs may be avoidable. Five of eight patients treated were able to stop taking about a dozen pills a day to suppress their immune systems. The drugs, which prevent rejection and stop tissue from a donated kidney from attacking the patient, can damage the transplant and cause diabetes, infections, heart disease and cancer. More

New kidney transplant policy will save more lives
U.S. News & World Report    Share    Share on FacebookTwitterShare on LinkedinE-mail article
From Nov. 19, 2012: For most of human history, kidney failure was a death sentence for those who encountered it. Today dialysis is effective in supporting people with kidney failure, but it too comes with limitations and potential complications. Kidney transplantation offers many the most effective long-term improvement in length and quality of life. More

Program may encourage living donors to give
a kidney

Renal & Urology News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
From July 30, 2012: Researchers at Johns Hopkins are testing a new program called "Live Donor Champion" that could encourage kidney donation from living donors. John Schieszer reports that it is a simple concept that could be adopted nationwide. More

NORA, Organ Recovery Transportation Specialists

NORA, the Nationwide Organ Recovery Transport Alliance can help your OPO or Transplant Center! NORA services are tailored to serve all of your organization's transportation needs. Whether by Air, Ground, Local or Long Distance, one call to NORA does it all! Click here for the full story.


60 lives, 30 kidneys, all linked
The New York Times    Share    Share on FacebookTwitterShare on LinkedinE-mail article
From Feb. 27, 2012: A history-making kidney transplant chain involving 60 people across the country was labeled Chain 124 by the nonprofit National Kidney Registry. It required lockstep coordination over four months among 17 hospitals in 11 states. It was born of innovations in computer matching, surgical technique and organ shipping, as well as the determination of a Long Island businessman named Garet Hil, who was inspired by his own daughter's illness to supercharge the notion of "paying it forward." More

Liver transplants for nonalcoholic steatohepatitis up 600 percent in 10 years
Physician's Briefing    Share    Share on FacebookTwitterShare on LinkedinE-mail article
From Jan. 3, 2012: The proportion of liver transplants performed in patients diagnosed with nonalcoholic steatohepatitis (NASH) increased dramatically from 1997-2003 to 2004-2010, but post-transplant survival in this population is excellent, with one-year survival rates near 88 percent, according to a study published online in Liver Transplantation. More

New era for organ donation and transplant in China
World Health Organization    Share    Share on FacebookTwitterShare on LinkedinE-mail article
From Nov. 5, 2012: China is establishing a new national system for organ donation and transplantation, based on Chinese cultural and societal norms, that aims to be ethical and sustainable. More

Risk factors for transplant-related urinary complications characterized
Renal & Urology News    Share    Share on FacebookTwitterShare on LinkedinE-mail article
From Jan. 30, 2012: A review of 635 kidney transplants performed at the University of Florida, Gainesville, has confirmed that transplanted kidneys with more than one renal artery put recipients at increased risk for urinary complications. The researchers found that renal-artery multiplicity in transplanted kidneys is associated with a statistically significant 2.5-fold higher risk of urinary complications compared with organs that have only one renal artery, according to a poster presentation at the American Society of Transplant Surgeons' 2012 Annual State of the Art Winter Symposium. More

Transplant cytomegalovirus infection test approved by FDA
Medical News Today    Share    Share on FacebookTwitterShare on LinkedinE-mail article
From July 16, 2012: The FDA has approved a DNA test — COBAS AmpliPrep/COBAS TaqMan CMV Test — to measure the efficacy of anti-viral treatment in solid organ transplant recipients who are being administered CMV (cytomegalovirus) antiviral therapy. The viral load test can determine, from a sample of the patient's blood plasma, levels of CMV nucleic acid. More


 

ASTS NewsBrief
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Tammy Gibson, Content Editor, 469.420.2677   
Contribute news

This edition of the ASTS NewsBrief was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here -- it's free!
Recent issues
Dec. 17, 2012
Dec. 3, 2012



7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063